Withania somnifera: a pre-clinical study on neuroregenerative therapy for stroke

作     者：Aparna Raghavan Zahoor A. Shah 

作者机构：Department of Medicinal and Biological Chemistry College of Pharmacy and Pharmaceutical Sciences University of Toledo Department of Pharmacology and Experimental Therapeutics College of Pharmacy and Pharmaceutical Sciences University of Toledo 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2015年第10卷第2期

页      面：183-185页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

主　　题：Withania somnifera a pre-clinical study on neuroregenerative therapy for stroke MCAO PARP WS 

摘      要：Stroke management exerts insurmountable societal and economic burden on the patient as well as their caregivers. In the year 2010 alone, the direct and indirect costs of stroke care amounted to 36.5 billion dollars （Go et al., 2014）. Despite concentrated efforts to develop a safe, effective drug for stroke, we have not discovered one since the introduction of recombinant tissue plasminogen activator （rtPA）--the standalone FDA-approved therapy for stroke. While rtPA is highly effective, it needs to be given within 3-4.5 hours of the onset of stroke symptoms （Zivin, 2009）. This is often complicated by the delay in the commencement of treatment due to preliminary inclusion parameters that are required to be ascertained before rtPA administration.